KMDA Earnings Prediction
The chart below shows how KMDA performed 10 days before and after its earnings report, based on data from the past quarters. Typically, KMDA sees a -2.21% change in stock price 10 days leading up to the earnings, and a -0.10% change 10 days following the report. On the earnings day itself, the stock moves by +2.01%. This data can give you a slight idea of what to expect for the next quarter's release.
KMDA Key Earning Data
2024/Q4
Year Over Year
Quarter Over Quarter
Total Revenue
--
--
--
Gross Margin
--
--
--
Operating Margin
--
--
--
Net Margin
--
--
--
EPS
--
--
--
No Data Available
KMDA Earnings Analysis
Kamada Ltd Corporation (KMDA.O) Earnings Conference Call
Positive
Record Revenue Achievement: Kamada Ltd. reported a record total revenue of $161 million for 2024, a 13% increase over 2023, meeting the top end of their guidance range.
Record Adjusted EBITDA Growth: Adjusted EBITDA reached a record $34.1 million, representing a 42% year-over-year growth, also at the top end of the expected range.
Cash Flow Performance: The company generated $47.6 million in cash from operations, resulting in a strong year-end cash position of $78.4 million.
Special Cash Dividend Announcement: Kamada declared a special cash dividend of $0.20 per share, reflecting confidence in the company's business prospects and commitment to shareholder value.
Revenue Forecast Increase: For fiscal 2025, Kamada forecasts annual revenues of $178 million to $182 million, indicating a projected increase of approximately 12% over 2024 results.
Biosimilar Product Launch Plans: The company successfully launched its first biosimilar product in Israel and plans to launch two additional biosimilars in 2025, with expected annual sales of $15 million to $20 million from this portfolio within five years.
Plasma Collection Expansion: Kamada opened its second plasma collection center in Houston, Texas, and completed construction of a third center in San Antonio, Texas, both expected to contribute annual revenues of $8 million to $10 million each at full capacity.
FDA Trial Error Rate Adjustment: The FDA confirmed a relaxed two-sided type 1 error rate for Kamada's inhaled AAT therapy trial, allowing for a reduced study sample size while maintaining statistical power.
Negative
Product-Driven Revenue Growth: Total revenue growth of 13% in 2024 was primarily driven by increased sales of KEDRAB and CYTOGAM, indicating reliance on a limited number of products for revenue generation.
Operating Expenses Increase: Operating expenses increased to $49.9 million in 2024 from $45.4 million in 2023, reflecting rising costs in sales and marketing as well as R&D, which could impact future profitability.
Net Income Decline Analysis: The reduction in net income in Q4 2024 compared to Q4 2023 was attributed to increased financial expenses related to the revaluation of contingent consideration, indicating potential volatility in future earnings.
Product Reliance Concerns: The company’s reliance on a few key products, such as KEDRAB, which had a minimum commitment of $135 million for the next three years, raises concerns about revenue stability if demand fluctuates.
EBITDA Growth Sustainability Concerns: The adjusted EBITDA growth of 42% in 2024, while impressive, may not be sustainable if operating expenses continue to rise at a similar rate, potentially squeezing margins in the future.
KMDA FAQs
How does KMDA typically perform around its earnings report dates?
Is Kamada Ltd (KMDA) Q4 2024 Earnings Call Summary positive or negative?
How can historical earnings data help predict future stock performance?
KMDA Earning Call Sentiment
Kamada Ltd. (NASDAQ:KMDA) Q4 2024 Earnings Call Transcript
KMDA.O
-2.07%Positive
Kamada reported strong financial performance with increased revenue, EBITDA, and net income, alongside improved gross margins. The company raised its EBITDA guidance and declared a special dividend, indicating confidence in future prospects. While there are regulatory and supply chain risks, the positive financial outlook and strategic growth initiatives, including expanding plasma centers and biosimilar launches, outweigh these concerns. The Q&A session confirmed management's optimism and strategic focus, though some answers lacked clarity. Overall, these factors suggest a positive stock price movement in the short term.
